

13ème Congrès Algérien de Rhumatologie de la LAAR
17-18-19 mai 2013, Sheraton - Alger

INSUFFISANCE RENALE RAPIDEMENT PROGRESSIVE SURVENANT CHEZ UNE PATIENTE SCLERODERMIQUE : QUEL(S) DIAGNOSTIC(S) RETENIR ?

A.TAHIAT^a, R. DJIDJIK^a, A. ALLAOUA^b, M. AMMI^c, S. BOUMEDIENE^d, M. GHAFFOR^a

- a. Laboratoire Central de **Biologie Médicale** ; CHU Beni Messous, Alger, Algérie*
- b. Service de **Néphrologie** ; CHU Beni Messous, Alger, Algérie*
- c. Service de **Réanimation, Pavillon des Urgences** ; CHU Beni Messous, Alger, Algérie*
- d. Service de **Médecine Interne** ; CHU Beni Messous, Alger, Algérie*

INTRODUCTION

[i] Sclérodermie Systémique (ScS)

✘ Maladie systémique autoimmune :

- Fibrose progressive atteignant la peau et les viscères,
- Altérations vasculaires (microangioathie),
- Autoanticorps : **AAN >95%** (*anti-topo1, ACA, anti-RNAP-III*)

✘ Atteintes viscérales :

- Digestive, pulmonaire, cardiaque et/ou **rénale**

INTRODUCTION

[ii] **Atteinte rénale au cours de la ScS**

✗ **Crise Rénale Sclérodermique (CRS) :**

- **2 à 5%** (premières années d'évolution de la ScS)
- **IRA** oligoanurique & **HTA** maligne (**90%**)
- **Microangiopathie thrombotique** (**43%**)
- **Anti-ARN polymérase III** (**≈33%**)

✗ **Autres étiologies :**

- Iatrogène, fonctionnelle ou **Glomérulonéphrite extracapillaire** (**vascularite à ANCA**)

INTRODUCTION

[iii] Vascularite associée aux ANCA & ScS

✗ Association peu fréquente :

- ANCA & ScS : 2 à 9% [2.9% : A. TAHIAT et al., 2013]
- Vascularite à ANCA & ScS : <50 cas rapportés (2013)

✗ Signes évocateurs :

- Insuffisance rénale **normotensive (GNRP) (83%)**, hémorragie alvéolaire (28%), ischémie digitale (13%), vascularite cutanée (10%),
- pANCA/anti-MPO (97%), anti-Scl-70 (77%)

✗ Biopsie rénale (GNRP) : Glomérulonéphrite extracapillaire

INTRODUCTION

[iii] Vascularite associée aux ANCA & ScS



Available online at
SciVerse ScienceDirect
www.sciencedirect.com

Elsevier Masson France
EM|consulte
www.em-consulte.com/en



Letter to the Editor

Clinical relevance of antineutrophil cytoplasmic antibodies in Algerian scleroderma patients

ARTICLE INFO


Keywords:
Systemic sclerosis
ANCA
Vasculitis

Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by vascular damage and progressive fibrosis involving

value obtained was more than 3.5U/ml and 9U/ml respectively. Other laboratory tests including inflammatory markers, urinalysis, rheumatoid factor (RF) and antinuclear antibodies (ANA) were also carried for each patient.

ANCA were positive in four cases (2.8%) Three patients were positive for p-ANCA with positivity for anti-MPO antibody. The fourth patient has shown negative result by IIFT but presented weak positivity for anti-PR3 antibody. Only one patient (Patient 1) had clinical features of AAV (Table 2). She presented with rapidly progressive renal failure with no evidence of scleroderma renal crisis (SRC) (lack of hypertension, microangiopathic hemolytic anemia and thrombocytopenia) and subsequently died from probable alveolar hemorrhage. The remaining three patients have shown no

INSUFFISANCE RENALE RAPIDEMENT PROGRESSIVE SURVENANT CHEZ UNE PATIENTE SCLERODERMIQUE. QUEL(S) DIAGNOSTIC(S) RETENIR ?



INSUFFISANCE RENALE RAPIDEMENT PROGRESSIVE SURVENANT CHEZ UNE PATIENTE SCLERODERMIQUE. QUEL(S) DIAGNOSTIC(S) RETENIR ?

✗ F. C, 63 ans, ScS diffuse (3 ans) :

- Phénomène de Raynaud,
- Atteinte œsophagienne,
- Pneumopathie interstitielle diffuse, HTAP,
- Polyarthralgies,
- Syndrome de Sjögern secondaire.
- **AAN :**
 - ✦ **Positifs : Ac anti-SSA et anti-RNP ;**
 - ✦ **Négatifs :** Ac anti-CENP, anti-Scl-70, anti-RNA polymérase III, anti-Th/To, anti-Fibrillarin, anti-NOR90 et anti-PM-Scl (100 et 75)

✗ Antécédents :

- Familiaux : RAS
- Personnels : **HTA** (depuis 6 ans)

INSUFFISANCE RENALE RAPIDEMENT PROGRESSIVE SURVENANT CHEZ UNE
PATIENTE SCLERODERMIQUE. QUEL(S) DIAGNOSTIC(S) RETENIR ?

✘ 21/05/2012 : IRRP

- Insuffisance rénale aiguë,
- HTA sévère (220/120 mm Hg),
- Créatinine : 45mg/L, Urée : 1,05 g/L,
- Clearance : 17 ml/min
- NFS : HB : 10,4 g/dl, Plaquettes : 209,000,
- Frotti sanguin : **pas de schizocytes**,
- Vs : 90 mm (à la première heure),
- CRP : 48 mg/L,
- Chimie des urines : protéinurie +++ & hématurie.

INSUFFISANCE RENALE RAPIDEMENT PROGRESSIVE SURVENANT CHEZ UNE
PATIENTE SCLERODERMIQUE. QUEL(S) DIAGNOSTIC(S) RETENIR ?

Quel diagnostic évoquer ?

INSUFFISANCE RENALE RAPIDEMENT PROGRESSIVE SURVENANT CHEZ UNE
PATIENTE SCLERODERMIQUE. QUEL(S) DIAGNOSTIC(S) RETENIR ?

**Une crise rénale
sclérodermique ?**

INSUFFISANCE RENALE RAPIDEMENT PROGRESSIVE SURVENANT CHEZ UNE PATIENTE SCLERODERMIQUE. QUEL(S) DIAGNOSTIC(S) RETENIR ?

✗ Traitement antihypertenseur :

- **Lopril** 75 mg/J (**IEC**)
- **Loxen** parentérale puis per Os 100 mg/J (**Inhibiteur calcique**)



✗ Après quelques jours d'observation :

- **Equilibre tensionnel** : 130/80 mm Hg
- **Fonction rénale** : pas d'amélioration (créatinine à 54 mg/l)

INSUFFISANCE RENALE RAPIDEMENT PROGRESSIVE SURVENANT CHEZ UNE PATIENTE SCLERODERMIQUE. QUEL(S) DIAGNOSTIC(S) RETENIR ?


✘ 17/06/2012 : Syndrome de détresse respiratoire aiguë

Téléthorax : opacités alvéolaires diffuses bilatérales




INSUFFISANCE RENALE RAPIDEMENT PROGRESSIVE SURVENANT CHEZ UNE PATIENTE SCLERODERMIQUE. QUEL(S) DIAGNOSTIC(S) RETENIR ?

✘ 17/06/2012 : Syndrome de détresse respiratoire aiguë



INSUFFISANCE RENALE RAPIDEMENT PROGRESSIVE SURVENANT CHEZ UNE PATIENTE SCLERODERMIQUE. QUEL(S) DIAGNOSTIC(S) RETENIR ?

✗ 17/06/2012 : Syndrome de détresse respiratoire aiguë



- Séance d'hémodialyse avec perte de poids (>2Kg) : **aucun effet**,
- Echocardiographie doppler : **pas d'insuffisance VG.**

INSUFFISANCE RENALE RAPIDEMENT PROGRESSIVE SURVENANT CHEZ UNE
PATIENTE SCLERODERMIQUE. QUEL(S) DIAGNOSTIC(S) RETENIR ?

Reconsidérons le diagnostic !



Hémorragie alvéolaire très probable



Glomérulonéphrite rapidement progressive
Protéinurie > 1 g/24H + hématurie



Tableau pneumo-rénal

INSUFFISANCE RENALE RAPIDEMENT PROGRESSIVE SURVENANT CHEZ UNE PATIENTE SCLERODERMIQUE. QUEL(S) DIAGNOSTIC(S) RETENIR ?

Reconsidérons le diagnostic !



Tableau pneumo-rénal



Syndrome inflammatoire CRP = 48, vs=90 mm



Pas de signes biologiques de MAT




Ac anti-RNA polymérase III négatif | U1 RNP



INSUFFISANCE RENALE RAPIDEMENT PROGRESSIVE SURVENANT CHEZ UNE
PATIENTE SCLERODERMIQUE. QUEL(S) DIAGNOSTIC(S) RETENIR ?

**Une vascularite associée aux
ANCA ?**

INSUFFISANCE RENALE RAPIDEMENT PROGRESSIVE SURVENANT CHEZ UNE
PATIENTE SCLERODERMIQUE. QUEL(S) DIAGNOSTIC(S) RETENIR ?



INSUFFISANCE RENALE RAPIDEMENT PROGRESSIVE SURVENANT CHEZ UNE
PATIENTE SCLERODERMIQUE. QUEL(S) DIAGNOSTIC(S) RETENIR ?

Quel diagnostic retenir ?

Anti-Neutrophil Antibody Associated Vasculitis in Systemic Sclerosis

Uri Arad, MD, PhD,* Alexandra Balbir-Gurman, MD,[†]
Keren Doenyas-Barak, MD,[‡] Mirit Amit-Vazina, MD,[§] Dan Caspi, MD,*
and Ori Elkayam, MD*

Objectives: To report 3 cases ANCA-associated vasculitis (AAV) that developed in patients suffering from systemic sclerosis (SSc) and to review previously reported cases.

Methods: We describe 3 patients diagnosed with SSc who developed severe AAV that presented as crescentic glomerulonephritis (GN) and/or alveolar hemorrhage. A retrospective review of the literature was performed using the PubMed database.

Results: The first patient presented with rapidly progressive renal failure and then with 2 episodes of massive alveolar hemorrhage. She was partially refractory to treatment with corticosteroids and cyclophosphamide but responded promptly to treatment with rituximab. The second patient suffered from 2 episodes of fulminant alveolar hemorrhage; the first responded to intravenous corticosteroids, but the second was fatal despite aggressive immune suppression with corticosteroids and cyclophosphamide. The third patient presented with a clinical picture compatible with scleroderma renal crisis (SRC) but was later diagnosed with crescentic GN and subsequently died from probable alveolar hemorrhage. Thirty-seven cases of AAV in SSc patients have been described in the English literature. Clinical manifestations include rapidly progressive GN, alveolar hemorrhage, limb ischemia, and vasculitic skin rash. In contrast to SRC that usually develops early in the course of SSc, ANCA-associated GN in SSc patients occurred later, after several years of illness. Hypertension, microangiopathic hemolytic anemia, and thrombocytopenia that are the hallmark of SRC were observed only in a minority of AAV cases. Almost all cases of AAV in SSc were positive for MPO-ANCA.

Conclusions: AAV in the setting of SSc is a diagnostic challenge. Differential diagnosis from SRC is crucial as treatment approach for these conditions completely differs. High doses of corticosteroids and immune suppression are advocated in severe AAV. In resistant cases, treatment with rituximab may be considered.

© 2011 Elsevier Inc. All rights reserved. *Semin Arthritis Rheum* 41:223-229

Keywords: systemic sclerosis, vasculitis, ANCA, alveolar hemorrhage

Systemic sclerosis (SSc) is an idiopathic disease characterized by progressive thickening of the skin and characteristic fibrotic involvement of multiple internal organs, most notably the kidneys, lungs, gastrointestinal tract,

and heart. The pathogenesis is incompletely understood, but entails a cellular and humoral autoimmune reaction that leads to vasculopathy and progressive visceral and vascular fibrosis. The most important renal complication in SSc is scleroderma renal crisis (SRC), estimated to affect 5 to 10% of all SSc patients (reviewed in (1,2)). SRC typically presents as a rapid onset of accelerated and often malignant hypertension, acute renal failure, and microangiopathic hemolytic anemia. Therapy with angiotensin-converting enzyme inhibitors dramatically improves the survival of patients with SRC. Overall, approximately two thirds of patients with SRC require renal replacement therapy and approximately one half of these patients will eventually recover sufficiently to discontinue dialysis (1). Renal recovery can occur up to 24 months after SRC.

*Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

[†]El Shein Rheumatology Unit, Rabin Health Care Campus and S. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

[‡]Department of Nephrology, Asaf Harosh Medical Center, Zerits and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

[§]Rheumatology Service, Asaf Harosh Medical Center, Zerits and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

The authors have no conflicts of interest to disclose.

Address reprint requests to Ori Elkayam, MD, Department of Rheumatology, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64230 Israel. E-mail: oriel14@post.tau.ac.il

with high titers of RF. D-penicillamine was discontinued, and treatment with weekly oral methotrexate (15 mg), low-dose prednisone (10 mg/daily), and hydroxychloroquine was instituted. Over the next several years, her disease gradually progressed with worsening sclerodactyly and gradual deterioration of the interstitial lung disease.

hips necessitated treatment with tumor necrosis factor- α blockers.

In 2006, while treated with etanercept, the patient sud-

Two days later, her hemoglobin level dropped from 12.3 g/dL to 10 g/dL and schistocytes were seen on blood smear. Hypertension persisted and the diagnosis of SRC was made. At this point, angiotensin-converting enzyme inhibitors were initiated. Serologic tests were positive for ANA with homogenous pattern, Scl-70, p-ANCA by immunofluorescence, and MPO by ELISA, whereas antibodies against dsDNA, GBM, Hepatitis B and C viruses, and cryoglobulins were all negative.

Renal biopsy, obtained on the fourth day of hospitalization, yielded 14 glomeruli, of which 1 was sclerotic and 10 contained epithelial crescents with fibrin deposits, and mixed lymphocytic and neutrophilic interstitial infiltrates. Blood vessels appeared normal.

The diagnosis of crescentic AAGN was made and treatment with IV methylprednisolone for 3 consecutive days, followed by high-dose oral prednisone and IV CYC (500 mg/m²), was initiated. During the following days, she developed progressive respiratory failure. Chest CT showed diffuse alveolar infiltrates. Despite an adequate

administration of high-dose IV immunoglobulins. Despite this treatment, the patient's condition continued to deteriorate and she died on the 32nd day of hospitalization.

Case 3

In February 2009, a 69-year-old woman was admitted to the internal medicine ward for investigation of weakness of 2 weeks' duration accompanied by mild abdominal pain, microscopic hematuria, and new onset renal failure.

On admission, she appeared comfortable. Her blood pressure was 180/95 mm Hg; heart rate was 90 beats per minute, and her temperature was 37.5°C. The physical

| | |
|-------------------------------|-------------|
| Diffuse | 57% (12/21) |
| Limited | 38% (8/21) |
| Sine | 5% (1/21) |
| Serology %, No. | |
| Scl-70 | 77% (27/35) |
| ACA | 20% (7/35) |
| Scl-70 + ACA negative | 5.7% (2/35) |
| p-ANCA | 97% (32/33) |
| c-ANCA | 3% (1/33) |
| MPO | 97% (34/35) |
| MPO | 97% (34/35) |
| PR3 | 3% (1/35) |
| MPO+PR3 negative | 3% (1/35) |
| Clinical manifestation %, no. | |
| RPGN | 83% (33/40) |
| Alveolar hemorrhage | 28% (11/40) |
| Limb ischemia | 13% (5/40) |
| Skin vasculitis | 10% (4/40) |
| Outcome %, no. | |
| Improved | 51% (18/35) |
| ESRD | 14% (5/35) |
| Death | 34% (12/35) |

until the appearance of overt AAV is about 9 years. The majority of patients suffered from the diffuse variant of SSc (57%), while about 38% had limited SSc.

In the AAV cohort, positive serology for Scl-70 was common (77%), while the frequency of this antibody

CONCLUSION

✘ Le diagnostic d'une GNEC, rentrant dans le cadre d'une vascularite à ANCA, chez un patient atteint d'une ScS constitue un véritable **challenge !!**

✘ **La mise en évidence d'ANCA par IFI et/ou par ELISA** est d'une aide incontestable au diagnostic différentiel que l'on peut préciser par biopsie rénale.

Merci pour votre attention

Vifs remerciements pour **DR. HABCHI** du service de néphrologie ; CHU Beni-Messous

